Inhibitory effect of dehydrozingerone on vascular smooth muscle cell function

Journal of Cardiovascular Pharmacology

Volumn 52, Issue 5, 2008, Pages 422-429

  Liu, Yizhen ^a   Dolence, Julia ^a   Ren, Jun ^a   Rao, Mna ^b   Sreejayan, Nair ^a  

^a UNIVERSITY OF WYOMING   (United States)

^b Divis Laboratories Limited   (India)

Author keywords

Curcumin; Dehydrozingerone; Platelet derived growth factor; Reactive oxygen species; Vascular disease

Indexed keywords

COLLAGEN; CURCUMIN; DEHYDROZINGERONE; HYDROGEN PEROXIDE; ISOEUGENOL; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROLINE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE; THYMIDINE; METHYL-3-METHOXY-4-HYDROXYSTYRYL KETONE; STYRENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; COLLAGEN SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HYDROLYSIS; IMMUNOBLOTTING; MALE; NONHUMAN; OXIDATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; STRUCTURE ACTIVITY RELATION; VASCULAR SMOOTH MUSCLE; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CELL MOTION; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; ENZYMOLOGY; INTIMA; METABOLISM; PHOSPHORYLATION; SPRAGUE DAWLEY RAT; THORACIC AORTA;

ANIMALS; AORTA, THORACIC; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; MUSCLE, SMOOTH, VASCULAR; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; STYRENES; TUNICA INTIMA;

EID: 59449097315     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31818aed93     Document Type: Article

References (32)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
2. Schwartz RS, Holmes DR Jr, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol. 1992; 20:1284-1293.
3. Strauss BH, Chisholm RJ, Keeley FW, et al. Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis. Circ Res. 1994;75:650-658.
4. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79:1283-1316.
5. Raines EW. PDGF and cardiovascular disease. Cytokine Growth Factor Rev. 2004;15:237-254.
6. 2, a necessary evil for cell signaling. Science. 2006;312:1882-1883.
7. Yang X, Thomas DP, Zhang X, et al. Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation. Arterioscler Thromb Vasc Biol. 2006;26: 85-90.
8. Kuo PC, Damu AG, Cherng CY, et al. Isolation of a natural antioxidant, dehydrozingerone from Zingiber officinale and synthesis of its analogues for recognition of effective antioxidant and antityrosinase agents. Arch Pharm Res. 2005;28:518-528.
9. Subramanian M, Sreejayan N, Rao MN, et al. Diminution of singlet oxygen-induced Dna damage by curcumin and related antioxidants. Mutat Res. 1994;311:249-255.
10. Sreejayan N, Rao MN. Curcuminoids as potent inhibitors of lipid peroxidation. J Pharm Pharmacol. 1994;46:1013-1016.
11. Sreejayan N, Lin Y, Hassid A. No attenuates insulin signaling and motility in aortic smooth muscle cells via protein tyrosine phosphatase 1B-mediated mechanism. Arterioscler Thromb Vasc Biol. 2002;22: 1086-1092.
12. Yigzaw Y, Poppleton HM, Sreejayan N, et al. Protein-tyrosine phosphatase-1B (Ptp1b) mediates the anti-migratory actions of Sprouty. J Biol Chem. 2003;278:284-288.
13. Sarkar R, Meinberg EG, Stanley JC, et al. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res. 1996; 78:225-230.
14. Sundaresan M, Yu ZX, Ferrans VJ, et al. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science. 1995;270:296-299.
15. Heffetz D, Bushkin I, Dror R, Zick Y. The insulinomimetic agents H2O2 and vanadate stimulate protein tyrosine phosphorylation in intact cells. J Biol Chem. 1990;265:2896-2902.
16. Kappert K, Sparwel J, Sandin A, et al. Antioxidants relieve phosphatase inhibition and reduce PDGF signaling in cultured VSMCs and in restenosis. Arterioscler Thromb Vasc Biol. 2006;26:2644-2651.
17. Meng TC, Fukada T, Tonks NK. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell. 2002;9:387-399.
18. Majesky MW, Reidy MA, Bowen-Pope DF, et al. PDGF ligand and receptor gene expression during repair of arterial injury. J Cell Biol. 1990; 111:2149-2158.
19. Ferns GA, Raines EW, Sprugel KH, et al. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 1991;253:1129-1132.
20. Sirois MG, Simons M, Edelman ER. Antisense oligonucleotide inhibition of Pdgfr-beta receptor subunit expression directs suppression of intimal thickening. Circulation. 1997;95:669-676.
21. Park SD, Jung JH, Lee HW, et al. Zedoariae rhizoma and curcumin inhibits platelet-derived growth factor-induced proliferation of human hepatic myofibroblasts. Int Immunopharmacol. 2005;5:555-569.
22. Cai H. Nad(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease. Circ Res. 2005;96:818-822.
23. Nedeljkovic ZS, Gokce N, Loscalzo J. Mechanisms of oxidative stress and vascular dysfunction. Postgrad Med J. 2003;79:195-199; quiz, 198-200.
24. Tonks NK. Redox redux: revisiting PTPS and the control of cell signaling. Cell. 2005;121:667-670.
25. Persson C, Savenhed C, Bourdeau A, et al. Site-selective regulation of platelet-derived growth factor beta receptor tyrosine phosphorylation by T-cell protein tyrosine phosphatase. Mol Cell Biol. 2004;24:2190-2201.
26. Buchdunger E, O'Reilly T, Wood J. Pharmacology of imatinib (Sti571). Eur J Cancer. 2002;38(Suppl 5):S28-S36.
27. Maresta A, Balducelli M, Latini R, et al. Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting. Catheter Cardiovasc Interv. 2005;64:375-382.
28. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of curcumin: a short review. Life Sci. 2006;78:2081-2087.
29. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23:363-398.
30. Lim GP, Chu T, Yang F, et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci. 2001;21:8370-8377.
31. Egan ME, Pearson M, Weiner SA, et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science. 2004;304:600-602.
32. Tamvakopoulos C, Dimas K, Sofianos ZD, et al. Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin. Clin Cancer Res. 2007;13:1269-1277.